TAKEDA PHARMA A/S: Financial statements 2026
CVR: 16406899
Source: annual report 2026, Danish Business Authority
01/04/2025 – 31/03/2026
TAKEDA PHARMA A/S (CVR 16406899) has filed annual accounts for 2026. In 2026, the company reported revenue of DKK 1,112,753,000 and a net result of DKK 88,641,000 compared with DKK 12,162,000 the year before. That is an increase of 0.9% compared with the year before. The profit margin was 8%. Equity in the 2026 report amounted to DKK 456,501,000. The solvency ratio was 73.2%. The company had 68 employees in the financial year.
- Revenue
- DKK 1,112,753,000
- Gross Profit
- DKK 215,662,000
- Profit/Loss
- DKK 88,641,000
- Equity
- DKK 456,501,000
- Total Assets
- DKK 623,480,000
- Employees
- 68
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2026 | 1.1B | 215.7M | 88.6M | 456.5M | 68 |
| 2025 | 1.1B | 119M | 12.2M | 368.3M | 68 |
| 2024 | 1.1B | 437.7M | 261.2M | 356M | 68 |
| 2023 | 1.1B | 120.6M | 13.6M | 94.9M | 70 |
| 2022 | 910.1M | 154M | 31.8M | 81.2M | 180 |
Official annual report
Find more companies like TAKEDA PHARMA A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2026
TAKEDA PHARMA A/S has won the tender "Amgros 2027 1.615.b" issued by Amgros I/S worth 67,284,330 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2027 1.1206.a" issued by Amgros I/S worth 239,972,960 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2027 2.691.b" issued by Amgros I/S worth 48,402,018 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2027 1.618.b" issued by Amgros I/S worth 32,174,840 DKK.
TAKEDA PHARMA A/S has won the tender "Amgros 2027 1.700.a" issued by Amgros I/S worth 419,427,587 DKK.
Contact info changed: new phone: 46771111, new email: [email protected] (August 21, 2026).
As of August 17, 2026, Enor Cerimagic has joined the board of directors of TAKEDA PHARMA A/S.
As of August 17, 2026, Malene Kelstrup has joined the board of directors of TAKEDA PHARMA A/S.
As of August 17, 2026, Koki Sato has joined the board of directors of TAKEDA PHARMA A/S.
As of August 17, 2026, Christian Ramskov has left the board of directors of TAKEDA PHARMA A/S.
About TAKEDA PHARMA A/S
TAKEDA PHARMA A/S is a Danish company of the type Aktieselskab based in Vallensbæk Strand, founded in 1984. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named NYCOMED DANMARK ApS and NYCOMED DANMARK A/S. The management consists of Enor Cerimagic. The board consists of Koki Sato (chair), Enor Cerimagic, Jesper Lindahl and Malene Kelstrup. The company is owned by Takeda Pharmaceuticals International AG. The company has 79 employees (2026). In 2026, the company reported revenue of DKK 1,112,753,000 and a net result of DKK 88,641,000 compared with DKK 12,162,000 the year before. Equity in the 2026 report amounted to DKK 456,501,000.